NSE filing, NSE: BIOCON. Summary written from the filing by ALFA Finder's alert engine.
Biocon Ltd: key numbers
- Share price
- ₹350.70
- Market cap
- ₹57,153 Cr
- Revenue (annual)
- ₹16,927 Cr
- Net profit (annual)
- ₹385.6 Cr
- P/E (TTM)
- 115.4×Sector 46.1×
- Promoter holding
- 44.68%+0.00% QoQ
- FII holding
- 8.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Biocon Ltd
All →Biocon Board Meeting Date
Biocon schedules a November 4, 2026 board meeting for Q2 FY27 unaudited results, plus an earnings call. Trading window stays closed until November 6, 2026.
Biocon Business Update
Biocon signed a licence agreement with Janssen to commercialise biosimilar Yesintek in nine more markets, including Australia, Brazil and China. No deal value is disclosed.
Biocon Other Announcement
Biocon Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing details the distribution of equity shares among various stakeholder categories.
Biocon Partnership
Biocon entered a global patent settlement and license agreement with Genentech, securing early launch dates for its biosimilar Pebrilzo® (bPertuzumab) across key global markets.
- From
- Genentech
Biocon Legal & Regulatory
Biocon received a GST demand order for ₹3.21 Crore, including tax, interest, and penalty. The company intends to file a rectification application or appeal.
- Value
- ₹3.21 Cr
Biocon Business Update
Biocon's Pertuzumab biosimilar received a positive CHMP opinion from the EMA, marking a milestone in its European regulatory path. Final European Commission approval is pending.
Other employee stock options announcements
All →Aye Finance Employee Stock Options
Aye Finance's employee welfare trust transferred 89,501 equity shares to grantees on exercising ESOP options. The share capital remains unchanged, so no new issuance occurs.
Aarti Pharmalabs Employee Stock Options
Aarti Pharmalabs granted 850 stock options to employees under its PSOP 2023 at Rs.5 exercise price. This is an employee incentive grant, not a capital raise.
OnEMI Technology Solutions Employee Stock Options
OnEMI Technology allotted 69,000 equity shares on exercise of employee stock options under the Kissht ESOP 2022 plan. The shares rank pari passu with existing equity.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bandhan Bank Employee Stock Options
Bandhan Bank's board granted 32,98,871 stock options under ESOP Series 1 (Tranche 9) at Rs 151.91 per option. The options vest over four years, with each option convertible into one equity share.
Maxvolt Energy Industries Employee Stock Options
Maxvolt Energy granted 5,01,726 ESOPs to six employees under its MEIL ESOP 2025 scheme at exercise prices of ₹30 and ₹45. Options vest over four years, with exercise windows following vesting.
- Execution
- Vesting over 4 years from grant (25% at 2nd, 25% at 3rd, 50% at 4th anniversary); exercise over 3 years from each vesting date